Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Liver Neoplasms 2Liposarcoma 2Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

Injections 3Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1SHR-1701 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignant Tumors × toripalimab × Clear all
NCT05102006 2025-06-03

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
80 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡